WVE vs. ACLX, ARWR, ACAD, PCVX, ADMA, PTGX, MENS, MIRM, KYMR, and MTSR
Should you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), ADMA Biologics (ADMA), Protagonist Therapeutics (PTGX), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), Kymera Therapeutics (KYMR), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.
WAVE Life Sciences vs. Its Competitors
Arcellx (NASDAQ:ACLX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
Arcellx has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.15, suggesting that its share price is 215% less volatile than the S&P 500.
In the previous week, Arcellx had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for Arcellx and 5 mentions for WAVE Life Sciences. Arcellx's average media sentiment score of 0.84 beat WAVE Life Sciences' score of 0.76 indicating that Arcellx is being referred to more favorably in the media.
96.0% of Arcellx shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Comparatively, 24.0% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Arcellx currently has a consensus target price of $114.31, indicating a potential upside of 45.15%. WAVE Life Sciences has a consensus target price of $20.33, indicating a potential upside of 202.13%. Given WAVE Life Sciences' higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Arcellx.
WAVE Life Sciences has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Arcellx's return on equity of -43.04% beat WAVE Life Sciences' return on equity.
WAVE Life Sciences has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Arcellx beats WAVE Life Sciences on 9 of the 17 factors compared between the two stocks.
Get WAVE Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
WAVE Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 9/25/2025 by MarketBeat.com Staff
Free WVE Stock Alerts